HPV-Based Screen-and-Treat Demonstration Project in Lilongwe

NACompletedINTERVENTIONAL
Enrollment

1,250

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2025

Conditions
HPV InfectionCervical CancerHIV Infections
Interventions
PROCEDURE

VIA and thermocoagulation

Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.

Trial Locations (1)

Unknown

University of North Carolina (UNC) Project-Malawi, Lilongwe

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

United States Agency for International Development (USAID)

FED

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT04092257 - HPV-Based Screen-and-Treat Demonstration Project in Lilongwe | Biotech Hunter | Biotech Hunter